SEC Form 4 · accession 0001140361-17-046579
REPLIGEN CORP · RGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Howard Benjamin
Officer — VP Business Development
Period of report
Dec 14, 2017
Accepted (ET)
Dec 18, 2017 · 5:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000730272
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 14, 2017 | M | 2,646 | $15.91 | A | 36,554 | D | |
| Common Stock | Dec 14, 2017 | M | 6,021 | $26.20 | A | 42,575 | D | |
| Common Stock | Dec 14, 2017 | M | 4,062 | $26.05 | A | 46,637 | D | |
| Common StockF2 | Dec 14, 2017 | S | 12,729 | $35.3394 | D | 33,908 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $15.91 | Dec 14, 2017 | M | 2,646 | D | — | Feb 27, 2024 | Common Stock | 2,646 | 0 | D |
| Stock Option (Right to Buy)F3 | $26.20 | Dec 14, 2017 | M | 6,021 | D | — | Feb 26, 2025 | Common Stock | 6,021 | 3,010 | D |
| Stock Option (Right to Buy)F3 | $26.05 | Dec 14, 2017 | M | 4,062 | D | — | Feb 26, 2026 | Common Stock | 4,062 | 8,124 | D |
Explanation of responses
- F1This option is currently exercisable.
- F2$35.3394 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.22 to $35.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date.